Literature DB >> 8586311

Comparison between transabdominal and transvaginal ultrasonography for identifying endometrial malignancies.

H Tsuda1, M Kawabata, K Kawabata, K Yamamoto, A Hidaka, N Umesaki.   

Abstract

Transvaginal ultrasound (TVS) is generally considered superior to transabdominal ultrasound (TAS) in the estimation of endometrial abnormalities. A disadvantage of TVS is the limited field of view. The purpose of this study is a comparison between TAS and TVS for endometrial cancer screening. Ninety-one postmenopausal women were included. They were evaluated by TAS, TVS, and endometrial tissue sampling. The mean endometrial thickness estimated by TVS was larger than that obtained by TAS (p < 0.0001). Sensitivity and specificity of TAS were 83.3 and 58.8% and of TVS 100 and 54.1%, respectively. We conclude that TVS might be superior to TAS, especially in patients with a retroflexed uterus.

Entities:  

Mesh:

Year:  1995        PMID: 8586311     DOI: 10.1159/000292351

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  3 in total

1.  Diagnostic value and agreement of transrectal in comparison with transvaginal sonography among women with abnormal uterine bleeding.

Authors:  Azadeh Akbari Sene; Farah Farzaneh; Afsaneh Mehrnami; Ali Mohammad Faizei; Ahad Alizadeh; Seyed Reza Saadat Mostafavi; Elnaz Ghaffari
Journal:  J Ultrasound       Date:  2022-01-15

2.  Transvaginal ultrasound in fertile patients with suspected appendicitis: an experience report of current practice.

Authors:  Malek Tabbara; Nikolaos Evangelopoulos; Luigi Raio; Vanessa Banz; Heinz Zimmermann; Corinne Kim-Fuchs; Aristomenis K Exadaktylos
Journal:  Emerg Med Int       Date:  2012-03-15       Impact factor: 1.112

3.  Office Hysteroscopy as a Valid Tool for Diagnosis of Genital Tract Lesions in Females with Intact Hymen.

Authors:  Hui-Yu Huang; Yi-Ting Huang; Kai-Yun Wu; Yu-Ying Su; Cindy Hsuan Weng; Chin-Jung Wang
Journal:  Biomed Res Int       Date:  2019-11-11       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.